Abstract
Huntingtons disease (HD) is a dominantly inherited neurodegenerative disorder caused by the expansion of a polymorphic CAG trinucleotide repeat encoding a poly-glutamine tract within the Huntingtin protein. GABAergic enkephalin neurons of the basal ganglia, which show the highest levels of expression of adenosine A2A receptors, are the most vulnerable in HD. Such a selective neuronal vulnerability, which occurs despite ubiquitous expression of mutant and normal Huntingtin, has suggested that adenosine A2A receptors might play a pathogenetic role in HD. In agreement, changes in A2A receptor expression and signaling have been reported in various experimental models of HD. The interpretation of the functional significance of the aberrant A2A receptor phenotype in HD mice is however complicated by the conflicting data so far reported on the potential neuroprotective and neurodegenerative effects of these receptors in the brain, with some data suggesting a potential pathogenetic role and some other data suggesting activation of trophic or protective pathways in neurons. The same complex profile has emerged in experimental models of HD, in which both A2A receptor agonists and antagonists have shown beneficial effects. The main aim of this review is to critically evaluate whether adenosine A2A receptors may represent a suitable target to develop drugs against HD.
Keywords: Adenosine A2A receptors, Huntington's disease, excitotoxicity, mitochondrial dysfunction, experimental models, BDNF, Dopamine, Heterodimers
Current Pharmaceutical Design
Title: A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Volume: 14 Issue: 15
Author(s): Patrizia Popoli, David Blum, Maria Rosaria Domenici, Sylvie Burnouf and Yijuang Chern
Affiliation:
Keywords: Adenosine A2A receptors, Huntington's disease, excitotoxicity, mitochondrial dysfunction, experimental models, BDNF, Dopamine, Heterodimers
Abstract: Huntingtons disease (HD) is a dominantly inherited neurodegenerative disorder caused by the expansion of a polymorphic CAG trinucleotide repeat encoding a poly-glutamine tract within the Huntingtin protein. GABAergic enkephalin neurons of the basal ganglia, which show the highest levels of expression of adenosine A2A receptors, are the most vulnerable in HD. Such a selective neuronal vulnerability, which occurs despite ubiquitous expression of mutant and normal Huntingtin, has suggested that adenosine A2A receptors might play a pathogenetic role in HD. In agreement, changes in A2A receptor expression and signaling have been reported in various experimental models of HD. The interpretation of the functional significance of the aberrant A2A receptor phenotype in HD mice is however complicated by the conflicting data so far reported on the potential neuroprotective and neurodegenerative effects of these receptors in the brain, with some data suggesting a potential pathogenetic role and some other data suggesting activation of trophic or protective pathways in neurons. The same complex profile has emerged in experimental models of HD, in which both A2A receptor agonists and antagonists have shown beneficial effects. The main aim of this review is to critically evaluate whether adenosine A2A receptors may represent a suitable target to develop drugs against HD.
Export Options
About this article
Cite this article as:
Popoli Patrizia, Blum David, Domenici Rosaria Maria, Burnouf Sylvie and Chern Yijuang, A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease, Current Pharmaceutical Design 2008; 14 (15) . https://dx.doi.org/10.2174/138161208784480117
DOI https://dx.doi.org/10.2174/138161208784480117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylation and Motor Neuron Degeneration
CNS & Neurological Disorders - Drug Targets PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design Development of Opioid Peptide Analogs for Pain Relief
Current Pharmaceutical Design A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry A Systematic Review on Traumatic Brain Injury Pathophysiology and Role of Herbal Medicines in its Management
Current Neuropharmacology HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Alzheimer Research Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
Current Drug Targets Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease
Current Genomics Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry